METASTATIC MELANOMA

This study tests a new drug (IOV-3001) that boosts the immune system, given together with a personalized cell therapy (lifileucel) in people with advanced melanoma that has stopped responding to standard treatments. About 42 adults with unresectable or metastatic melanoma will ta…

This study tests a new drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults with can…

This study tests whether adding a liver-directed chemotherapy (HEPZATO KIT) to an immunotherapy drug combination (Opdualag) is safe and works better than immunotherapy alone for people with metastatic melanoma that has spread to the liver. About 15 participants who have not had p…

This study tests a new treatment called [212Pb]VMT01, which delivers targeted radiation directly to melanoma cells. It is for people with advanced melanoma that has not responded to prior treatments. The study will see if this therapy is safe and effective when used alone or with…

This study tests two drugs—cabozantinib and nivolumab—in people with advanced melanoma or head and neck cancer that has stopped responding to other treatments. The goal is to see if the combination can shrink or stabilize the cancer, and whether certain tumor biomarkers can predi…

This study tests whether a blood test (ctDNA) can help doctors decide when to add a third immunotherapy drug (ipilimumab) to a two-drug combination (nivolumab and relatlimab) for people with advanced melanoma. About 90 adults with metastatic or advanced melanoma will participate.…

This early-stage trial tests whether injecting a standard flu vaccine directly into melanoma tumors can help shrink them. The study includes 36 adults with stage I to IV melanoma who have at least one tumor that can be injected. The main goals are to check safety and find the bes…

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapies. OBX-115 uses a patient's own tumor-fighting immune cells (TILs) that have been modified to produc…

This early-phase trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for advanced uveal melanoma, undifferentiated pleomorphic sarcoma, or dedifferentiated liposarcoma. About 30 participants will have their tumor removed, have …

This study tests whether adding a personalized cell therapy (lifileucel, made from a patient's own tumor-fighting immune cells) to the standard immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated yet. A…

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with two anti-rejection medications (sirolimus and prednisone) can control advanced skin cancer in kidney transplant recipients without losing the transplanted kidney. About 16 adults with skin …

This early-phase study tests adding nilotinib to standard targeted therapy for people with advanced melanoma that has a BRAF V600 mutation and has stopped responding to previous BRAF/MEK inhibitor treatment. About 30 participants will receive the drug combination to find the safe…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…

This early-stage trial tests a new treatment called Adze1.C for adults with advanced melanoma that hasn't responded to standard therapies. Adze1.C is a specially designed virus that infects and kills cancer cells and may also help the immune system fight tumors. The main goals ar…

This early-phase study tests a new treatment for advanced melanoma that has stopped responding to standard immunotherapy. It combines specially trained natural killer cells (either from the patient or a donor) with two immunotherapy drugs, nivolumab and relatlimab. The goal is to…

This study is for people with metastatic melanoma whose cancer has started growing in a few spots despite treatment. Researchers want to see if giving high-dose, precise radiation to those spots can delay further spread. About 52 adults will take part, and the main goal is to see…

This study tests whether combining two drugs, pembrolizumab and aldesleukin, can shrink tumors in people with advanced melanoma or kidney cancer that has not responded to standard treatments. Participants receive the drugs through an IV during two short hospital stays, followed b…

This study tests two drugs, binimetinib and encorafenib, in people with advanced melanoma that has spread to the brain. The drugs block enzymes that help cancer cells grow. The goal is to see if this combination can control the disease and improve survival. About 35 adults with a…

This study tests whether a combination of targeted drugs (encorafenib and binimetinib) plus an immunotherapy (nivolumab) works better than two immunotherapies (ipilimumab and nivolumab) for people with BRAF-V600 mutant melanoma that has spread to the brain. About 112 adults with …

This study tests whether adding an experimental drug (GB1211) to a standard immunotherapy (pembrolizumab) works better than the immunotherapy alone for people with advanced melanoma or head and neck cancer. About 92 adults whose cancer has spread or cannot be removed will take pa…

This study tests whether freezing part of a growing tumor (cryoablation) combined with two immunotherapy drugs (ipilimumab and nivolumab) can help control advanced melanoma that stopped responding to prior treatment. About 37 adults with unresectable melanoma will receive the com…

This study tests whether giving a lower, less frequent dose of the cancer drug atezolizumab can still control tumors while causing fewer side effects. About 30 adults with advanced lung, liver, skin, or sarcoma cancers will receive the drug alone or with other treatments. Researc…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This program offers a special cell therapy called AMTAGVI to people with advanced melanoma that cannot be removed by surgery or has spread. The treatment is made from the patient's own immune cells and is normally only given when it meets strict quality standards. Here, patients …

This study tests a drug called avapritinib in people with advanced solid tumors that have spread and have specific gene changes (CKIT or PDGFRA mutations). The drug works by blocking enzymes that help cancer cells grow. The goal is to see if avapritinib can shrink or control thes…

This early-phase study tests a combination of two ways to give the immunotherapy drug nivolumab: through a vein and directly into the fluid around the spine. It is for people with melanoma or lung cancer that has spread to the lining of the brain or spinal cord (leptomeningeal di…

This study tests a new treatment for advanced melanoma that has spread to the brain. It combines chemotherapy (temozolomide) with specially grown immune cells from a healthy donor (called NK cells). The goal is to see if this combination is safe and can shrink brain tumors. About…

This study is testing an experimental drug called mirdametinib in people with advanced melanoma that has a specific genetic change (an NF1 mutation) and has continued to grow despite previous immunotherapy. The main goals are to see if the drug is safe and if it can slow or stop …

This study compares two types of radiation therapy for people whose cancer has spread to the brain. One group gets a single high dose of radiation, while the other gets three smaller doses over several days. The goal is to see if the three-dose approach works better at controllin…

This study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…

This study tests whether adding cryoablation (freezing cancer cells) to standard radiation therapy provides better pain relief for people with cancer that has spread to the bones. About 40 adults with certain advanced cancers (like prostate, kidney, or colorectal) will be enrolle…

This study tests if a short bout of exercise right before immunotherapy (Nivolumab and Ipilimumab) can boost the immune system and improve treatment effectiveness in people with advanced melanoma. Researchers will check if this approach is practical for patients and whether it in…

This study looks at how effective first-line immunotherapy is for people with metastatic melanoma treated at the Institute of Oncology Ljubljana in Slovenia. Researchers will track tumor shrinkage, time to progression, and side effects, and analyze blood, stool, and body fluids t…

This study looks at how immune cells called T cells change in people with advanced melanoma, lung cancer, or other solid tumors during anti-PD-1 treatment. Researchers will measure specific markers in blood samples to see if they can predict whether the therapy is working or if r…

This study watches 50 people who already received replimune immunotherapy for cancers like melanoma or liver cancer. The goal is to see if any side effects show up years later. No new treatment is given—just regular checkups for 5 years.

This study aims to create an artificial intelligence tool that analyzes photos of skin damage around a melanoma scar to predict whether a patient will respond to anti-PD-1 immunotherapy. Researchers will enroll 700 adults with advanced melanoma or other skin cancers. The goal is …

This study is looking at how effective immunotherapy is as a first treatment for metastatic melanoma that has spread. Researchers will check if a marker called PD-L1, found in tumors and blood, can help predict who will respond well. About 100 adults with advanced melanoma will t…